September 28, 2023
LungLife AI, Inc.(the “Company” or “LungLife”) LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, provides an update on the Company’s clinical validation study for its LungLB® test. As stated in the Company’s half-year report on 8 August 2023, LungLife is currently focussed on preparing data from […]
• Read MoreAugust 14, 2023
LungLife AI, Inc. (the “Company” or “LungLife”) Director share purchases LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces that it has received notification of the following transactions in the Company’s common shares of US $0.0001 each (“Common Shares”) undertaken by directors. On 14 August 2023, […]
• Read MoreAugust 8, 2023
LungLife AI, Inc. (the “Company” or “LungLife”) Half-year Report LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer announces its unaudited half-year report for the six months ended 30 June 2023. Operational Highlights: Completed enrolment of the Company’s 425-participant pivotal clinical validation study in May, in line […]
• Read MoreAugust 3, 2023
3 August 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Notice of Results Investor Presentation LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, will announce its unaudited half-year report for the six months ended 30 June 2023 on Tuesday 8 August 2023. Investor presentation Paul Pagano, […]
• Read MoreJune 6, 2023
6 June 2023 LungLife AI, Inc. (the “Company” or “LungLife”) LungLB® study demonstrating high performance published in peer-reviewed journal LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the publication of successful performance results for the Company’s blood-based LungLB® test from a multi-site prospective study in patients with indeterminate pulmonary […]
• Read MoreMay 23, 2023
23 May 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Enrolment completed for pivotal validation study of LungLB® Company to work with clinical sites to ensure data quality ahead of analysis and readout LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the completion of enrolment for its prospective, pivotal […]
• Read MoreMay 15, 2023
15 May 2023 LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Six Monthly Return LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six monthly update on its block listing pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies: Name of applicant: […]
• Read MoreMay 4, 2023
4 May 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Result of Annual General Meeting LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at its Annual General Meeting, held at earlier today, all 10 resolutions put to members were passed on a poll. The number of votes lodged […]
• Read MoreMay 2, 2023
2 May 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Confirmation of AGM LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, confirms that its Annual General Meeting ("AGM") will be held at 3:00 P.M. (BST) on Thursday 4 May 2023, at Investec Bank plc, 30 Gresham Street, London, EC2V 7QP. […]
• Read MoreApril 6, 2023
06 April 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Publication of Annual Report and Accounts & Notice of AGM LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that the Annual Report and Accounts, Notice of Annual General Meeting ("AGM"), Form of Direction and associated Form of Proxy are now […]
• Read More
LungLife AI licensure/accreditation information posted here.